143 related articles for article (PubMed ID: 3125414)
1. Induction of resistance in mice by the capsular polysaccharide antigens of Staphylococcus aureus.
Yoshida K; Umeda A; Ohshima Y
Microbiol Immunol; 1987; 31(7):649-56. PubMed ID: 3125414
[TBL] [Abstract][Full Text] [Related]
2. Protection of mice by a pseudodiffuse strain of Staphylococcus aureus possessing polyvalent capsular type antigen.
Chomarat M; Ichiman Y; Yoshida K
J Med Microbiol; 1989 Feb; 28(2):129-36. PubMed ID: 2915365
[TBL] [Abstract][Full Text] [Related]
3. Purified capsular polysaccharide-induced immunity to Staphylococcus aureus infection.
Lee JC; Perez NE; Hopkins CA; Pier GB
J Infect Dis; 1988 Apr; 157(4):723-30. PubMed ID: 3346565
[TBL] [Abstract][Full Text] [Related]
4. Cross protection between an encapsulated strain of Staphylococcus hyicus and encapsulated strains of Staphylococcus aureus.
Yoshida K; Ichiman Y; Umeda A
J Appl Bacteriol; 1988 Dec; 65(6):491-9. PubMed ID: 3243729
[TBL] [Abstract][Full Text] [Related]
5. Isolation of a serologically different compact-colony-forming active substance from strains of Staphylococcus aureus.
Yoshida K; Ohtomo T; Suganuma M
Microbiol Immunol; 1990; 34(10):801-8. PubMed ID: 2077365
[TBL] [Abstract][Full Text] [Related]
6. O-Acetylation is essential for functional antibody generation against Staphylococcus aureus capsular polysaccharide.
Scully IL; Pavliak V; Timofeyeva Y; Liu Y; Singer C; Anderson AS
Hum Vaccin Immunother; 2018 Jan; 14(1):81-84. PubMed ID: 29182428
[TBL] [Abstract][Full Text] [Related]
7. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.
Fattom AI; Sarwar J; Ortiz A; Naso R
Infect Immun; 1996 May; 64(5):1659-65. PubMed ID: 8613375
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.
Cheng BL; Nielsen TB; Pantapalangkoor P; Zhao F; Lee JC; Montgomery CP; Luna B; Spellberg B; Daum RS
Hum Vaccin Immunother; 2017 Jul; 13(7):1609-1614. PubMed ID: 28422567
[TBL] [Abstract][Full Text] [Related]
9. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine.
Maira-Litrán T; Kropec A; Goldmann DA; Pier GB
Infect Immun; 2005 Oct; 73(10):6752-62. PubMed ID: 16177353
[TBL] [Abstract][Full Text] [Related]
10. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen.
McKenney D; Pouliot KL; Wang Y; Murthy V; Ulrich M; Döring G; Lee JC; Goldmann DA; Pier GB
Science; 1999 May; 284(5419):1523-7. PubMed ID: 10348739
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of a Staphylococcus aureus capsular polysaccharide-protein conjugate prepared by a low cost technique: a proof-of-concept study.
Pujato N; Díaz G; Barbagelata MS; Vicco MH; Calvinho LF; Marcipar IS
Appl Biochem Biotechnol; 2015 Jan; 175(1):141-54. PubMed ID: 25245681
[TBL] [Abstract][Full Text] [Related]
12. Protective antibodies in human sera against encapsulated strains of Staphylococcus epidermidis.
Ichiman Y; Yamada T; Yoshida K
J Appl Bacteriol; 1987 Aug; 63(2):165-9. PubMed ID: 3654405
[TBL] [Abstract][Full Text] [Related]
13. [Chemical and immunogenic properties of the capsular antigen of Staphylococcus aureus. III. Protective activity of capsular antigen in experiments on mice].
Akatov AK; Prokhorov VIa; Witte W; Kühn M; Seltmann G
Zh Mikrobiol Epidemiol Immunobiol; 1978 Nov; (11):47-52. PubMed ID: 726743
[TBL] [Abstract][Full Text] [Related]
14. Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible?
Shinefield HR
Vaccine; 2006 Apr; 24 Suppl 2():S2-65-9. PubMed ID: 16823932
[TBL] [Abstract][Full Text] [Related]
15. Reactivity of type-specific monoclonal antibodies with Staphylococcus aureus clinical isolates and purified capsular polysaccharide.
Nelles MJ; Niswander CA; Karakawa WW; Vann WF; Arbeit RD
Infect Immun; 1985 Jul; 49(1):14-8. PubMed ID: 4008045
[TBL] [Abstract][Full Text] [Related]
16. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli.
Wacker M; Wang L; Kowarik M; Dowd M; Lipowsky G; Faridmoayer A; Shields K; Park S; Alaimo C; Kelley KA; Braun M; Quebatte J; Gambillara V; Carranza P; Steffen M; Lee JC
J Infect Dis; 2014 May; 209(10):1551-61. PubMed ID: 24308931
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis.
Nemeth J; Lee JC
Infect Immun; 1995 Feb; 63(2):375-80. PubMed ID: 7821999
[TBL] [Abstract][Full Text] [Related]
18. Vaccine potential of poly-1-6 beta-D-N-succinylglucosamine, an immunoprotective surface polysaccharide of Staphylococcus aureus and Staphylococcus epidermidis.
Mckenney D; Pouliot K; Wang Y; Murthy V; Ulrich M; Döring G; Lee JC; Goldmann DA; Pier GB
J Biotechnol; 2000 Sep; 83(1-2):37-44. PubMed ID: 11000458
[TBL] [Abstract][Full Text] [Related]
19. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines.
Robbins JB; Schneerson R; Horwith G; Naso R; Fattom A
Am Heart J; 2004 Apr; 147(4):593-8. PubMed ID: 15077073
[TBL] [Abstract][Full Text] [Related]
20. Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy.
Skurnik D; Kropec A; Roux D; Theilacker C; Huebner J; Pier GB
Clin Infect Dis; 2012 Nov; 55(9):1188-97. PubMed ID: 22806596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
